SillaJen, Transgene fall with latest oncolytic virus setback

SillaJen, Transgene fall with latest oncolytic virus setback

Source: 
BioCentury
snippet: 

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about the virus' specific construct and trial design.